Recent 8-K filings for IKT

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 12, 2026 20:31 UTC earnings item 2.02item 9.01

  Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH

source · IKT on sec.gov